OCE-205, a Selective V1a Partial Agonist, Reduces Portal Pressure in Rat Models of Portal Hypertension

References

• Tellez L, Guerrero A. Management of liver decompensation in advanced liver disease (renal impairment, liver failure, adrenal insufficiency, cardiopulmonary complications). Clin Drug Investig. 2022;42(Suppl 1):15–23. doi:10.1007/s40261-022-01149-3
   PubMed Web of Science ®Google Scholar
• Biggins SW, Angeli P, Garcia-Tsao G, et al. Diagnosis, evaluation, and management of ascites, spontaneous bacterial peritonitis and hepatorenal syndrome: 2021 practice guidance by the American association for the study of liver diseases. Hepatology. 2021;74(2):1014–1048. doi:10.1002/hep.31884
   PubMed Web of Science ®Google Scholar
• Smith A, Baumgartner K, Bositis C. Cirrhosis: diagnosis and management. Am Fam Physician. 2019;100(12):759–770.
   PubMed Web of Science ®Google Scholar
• Moller S, Bendtsen F. The pathophysiology of arterial vasodilatation and hyperdynamic circulation in cirrhosis. Liver Int. 2018;38(4):570–580. doi:10.1111/liv.13589
   PubMed Web of Science ®Google Scholar
• Ginès P, Solà E, Angeli P, Wong F, Nadim MK, Kamath PS. Hepatorenal syndrome. Nat Rev Dis Primers. 2018;4(1):23. doi:10.1038/s41572-018-0022-7
   PubMedGoogle Scholar
• Harper D, Chandler B. Splanchnic circulation. BJA Educ. 2015;16(2):66–71. doi:10.1093/bjaceaccp/mkv017
   Google Scholar
• Velez JCQ. Hepatorenal syndrome type 1: from diagnosis ascertainment to goal-oriented pharmacologic therapy. Kidney360. 2022;3(2):382–395. doi:10.34067/KID.0006722021
   PubMedGoogle Scholar
• Velez JC, Nietert PJ. Therapeutic response to vasoconstrictors in hepatorenal syndrome parallels increase in mean arterial pressure: a pooled analysis of clinical trials. Am J Kidney Dis. 2011;58(6):928–938. doi:10.1053/j.ajkd.2011.07.017
   PubMed Web of Science ®Google Scholar
• European Association for The Study of the Liver. EASL clinical practice guidelines for the management of patients with decompensated cirrhosis. J Hepatol. 2018;69(2):406–460. doi:10.1016/j.jhep.2018.03.024
   PubMed Web of Science ®Google Scholar
• Treschan TA, Peters J, Warltier D. The vasopressin system: physiology and clinical strategies. Anesthesiology. 2006;105(3):599. doi:10.1097/00000542-200609000-00026
   PubMed Web of Science ®Google Scholar
• Barberis C, Mouillac B, Durroux T. Structural bases of vasopressin/oxytocin receptor function. J Endocrinol. 1998;156(2):223–229. doi:10.1677/joe.0.1560223
   PubMed Web of Science ®Google Scholar
• Koshimizu TA, Nakamura K, Egashira N, Hiroyama M, Nonoguchi H, Tanoue A. Vasopressin V1a and V1b receptors: from molecules to physiological systems. Physiol Rev. 2012;92(4):1813–1864. doi:10.1152/physrev.00035.2011
   PubMed Web of Science ®Google Scholar
• Albert RE, Smith WW, Eichna LW. Hemodynamic changes associated with fluid retention induced in noncardiac subjects by corticotropin (ACTH) and cortisone; comparison with the hemodynamic changes of congestive heart failure. Circulation. 1955;12(6):1047–1056. doi:10.1161/01.cir.12.6.1047
   PubMed Web of Science ®Google Scholar
• Donnellan F, Cullen G, Hegarty JE, McCormick PA. Ischaemic complications of glypressin in liver disease: a case series. Br J Clin Pharmacol. 2007;64(4):550–552. doi:10.1111/j.1365-2125.2007.02921.x
   PubMed Web of Science ®Google Scholar
• Gulberg V, Bilzer M, Gerbes AL. Long-term therapy and retreatment of hepatorenal syndrome type 1 with ornipressin and dopamine. Hepatology. 1999;30(4):870–875. doi:10.1002/hep.510300430
   PubMed Web of Science ®Google Scholar
• Glavas M, Gitlin-Domagalska A, Debowski D, Ptaszynska N, Legowska A, Rolka K. Vasopressin and its analogues: from natural hormones to multitasking peptides. Int J Mol Sci. 2022;23(6):3068. doi:10.3390/ijms23063068
   PubMed Web of Science ®Google Scholar
• Karwa R, Woodis CB. Midodrine and octreotide in treatment of cirrhosis-related hemodynamic complications. Ann Pharmacother. 2009;43(4):692–699. doi:10.1345/aph.1L373
   PubMed Web of Science ®Google Scholar
• Israelsen M, Krag A, Allegretti AS, et al. Terlipressin versus other vasoactive drugs for hepatorenal syndrome. Cochrane Database Syst Rev. 2017;9:CD011532. doi:10.1002/14651858.CD011532.pub2
   PubMed Web of Science ®Google Scholar
• Smythe CM, Nickel JF, Bradley SE. The effect of epinephrine (USP), L-epinephrine, and L -norepinephrine on glomerular filtration rate, renal plasma flow, and the urinary excretion of sodium, potassium, and water in normal man. J Clin Investig. 1952;31(5):499–506. doi:10.1172/JCI102634
   PubMed Web of Science ®Google Scholar
• Mallinckrodt Pharmaceuticals. TERLIVAZ [terlipressin] for injection. 2022; Available from: https://www.terlivaz.com/PI/.
   Google Scholar
• U.S. Food & Drug Administration. FDA approves treatment to improve kidney function in adults with hepatorenal syndrome; 2022. Available from: https://www.fda.gov/drugs/news-events-human-drugs/fda-approves-treatment-improve-kidney-function-adults-hepatorenal-syndrome. Accessed July 5, 2023.
   Google Scholar
• Jamil K, Pappas SC, Devarakonda KR. In vitro binding and receptor-mediated activity of terlipressin at vasopressin receptors V1 and V2. J Exp Pharmacol. 2018;10:1–7. doi:10.2147/JEP.S146034
   PubMedGoogle Scholar
• Colson PH, Virsolvy A, Gaudard P, et al. Terlipressin, a vasoactive prodrug recommended in hepatorenal syndrome, is an agonist of human V1, V2 and V1B receptors: implications for its safety profile. Pharmacol Res. 2016;113(Pt A):257–264. doi:10.1016/j.phrs.2016.08.027
   PubMedGoogle Scholar
• Ouattara A, Landi M, Le Manach Y, et al. Comparative cardiac effects of terlipressin, vasopressin, and norepinephrine on an isolated perfused rabbit heart. Anesthesiology. 2005;102(1):85–92. doi:10.1097/00000542-200501000-00016
   PubMed Web of Science ®Google Scholar
• Henderson KK, Byron KL. Vasopressin-induced vasoconstriction: two concentration-dependent signaling pathways. J Appl Physiol. 2007;102(4):1402–1409. doi:10.1152/japplphysiol.00825.2006
   PubMed Web of Science ®Google Scholar
• Moller S, Hansen EF, Becker U, Brinch K, Henriksen JH, Bendtsen F. Central and systemic haemodynamic effects of terlipressin in portal hypertensive patients. Liver. 2000;20(1):51–59. doi:10.1034/j.1600-0676.2000.020001051.x
   PubMedGoogle Scholar
• Freeman JG, Barton JR, Record CO. Haemodynamic responses to 1.25 and 2 mg of terlipressin intravenously in man. Aliment Pharmacol Ther. 1988;2(4):361–367. doi:10.1111/j.1365-2036.1988.tb00709.x
   PubMed Web of Science ®Google Scholar
• Sarma P, Muktesh G, Singh RS, et al. Terlipressin-induced ischemic complications: a systematic review of published case reports. J Pharmacol Pharmacother. 2018;9(2):76–85. doi:10.4103/jpp.JPP_23_18
   Web of Science ®Google Scholar
• Boyer TD, Sanyal AJ, Wong F, et al. Terlipressin plus albumin is more effective than albumin alone in improving renal function in patients with cirrhosis and hepatorenal syndrome type 1. Gastroenterology. 2016;150(7):1579–1589 e2. doi:10.1053/j.gastro.2016.02.026
   PubMed Web of Science ®Google Scholar
• Krag A, Bendtsen F, Pedersen EB, Holstein-Rathlou NH, Moller S. Effects of terlipressin on the aquaretic system: evidence of antidiuretic effects. Am J Physiol Renal Physiol. 2008;295(5):F1295–F1300. doi:10.1152/ajprenal.90407.2008
   PubMed Web of Science ®Google Scholar
• Messmer AS, Zingg C, Müller M, Gerber JL, Schefold JC, Pfortmueller CA. Fluid overload and mortality in adult critical care patients-a systematic review and meta-analysis of observational studies. Crit Care Med. 2020;48(12):1862–1870. doi:10.1097/ccm.0000000000004617
   PubMed Web of Science ®Google Scholar
• Schrier RW, Wang W. Acute renal failure and sepsis. N Engl J Med. 2004;351(2):159–169. doi:10.1056/NEJMra032401
   PubMed Web of Science ®Google Scholar
• Griffin BR, Liu KD, Teixeira JP. Critical care nephrology: core curriculum 2020. Am J Kidney Dis. 2020;75(3):435–452. doi:10.1053/j.ajkd.2019.10.010
   PubMed Web of Science ®Google Scholar
• Zhu BT. Rational design of receptor partial agonists and possible mechanisms of receptor partial activation: a theory. J Theor Biol. 1996;181(3):273–291. doi:10.1006/jtbi.1996.0130
   PubMed Web of Science ®Google Scholar
• Croston G, Cable E, Toy J, et al. Selective partial agonism of vasopressin 1a receptors in vitro by OCE-205. J Pharmacol Exp Ther. 2023;2023:1.
   Google Scholar
• Konigshofer P, Brusilovskaya K, Schwabl P, Reiberger T. Animal models of portal hypertension. Biochim Biophys Acta Mol Basis Dis. 2019;1865(5):1019–1030. doi:10.1016/j.bbadis.2018.07.018
   PubMed Web of Science ®Google Scholar
• Bai Z, An Y, Guo X, et al. Role of terlipressin in cirrhotic patients with ascites and without hepatorenal syndrome: a systematic review of current evidence. Can J Gastroenterol Hepatol. 2020;2020:5106958. doi:10.1155/2020/5106958
   PubMed Web of Science ®Google Scholar
• Francque S, Wamutu S, Chatterjee S, et al. Non-alcoholic steatohepatitis induces non-fibrosis-related portal hypertension associated with splanchnic vasodilation and signs of a hyperdynamic circulation in vitro and in vivo in a rat model. Liver Int. 2010;30(3):365–375. doi:10.1111/j.1478-3231.2009.02136.x
   PubMed Web of Science ®Google Scholar
• Ryou M, Stylopoulos N, Baffy G. Nonalcoholic fatty liver disease and portal hypertension. Explor Med. 2020;1:149–169. doi:10.37349/emed.2020.00011
   PubMedGoogle Scholar
• Rogers AE, Newberne PM. Animal model: fatty liver and cirrhosis in lipotrope-deficient male rats. Am J Pathol. 1973;73(3):817–820.
   PubMedGoogle Scholar
• Oberti F, Veal N, Kaassis M, et al. Hemodynamic effects of terlipressin and octreotide administration alone or in combination in portal hypertensive rats. J Hepatol. 1998;29(1):103–111. doi:10.1016/s0168-8278(98)80184-0
   PubMed Web of Science ®Google Scholar
• Blei AT, Groszmann RJ, Gusberg R, Conn HO. Comparison of vasopressin and triglycyl-lysine vasopressin on splanchnic and systemic hemodynamics in dogs. Dig Dis Sci. 1980;25(9):688–694. doi:10.1007/BF01308328
   PubMed Web of Science ®Google Scholar
• Pereira RM, Dos Santos RA, Oliveira EA, et al. Development of hepatorenal syndrome in bile duct ligated rats. World J Gastroenterol. 2008;14(28):4505–4511. doi:10.3748/wjg.14.4505
   PubMed Web of Science ®Google Scholar
• Martinez-Prieto C, Ortiz MC, Fortepiani LA, Ruiz-Macia J, Atucha NM, Garcia-Estan J. Haemodynamic and renal evolution of the bile duct-ligated rat. Clin Sci. 2000;98(5):611–617. doi:10.1042/cs0980611
   Web of Science ®Google Scholar
• Gervaz P, Scholl B, Gillet M. Permanent access to the portal vein in rats: an experimental model. Eur Surg Res. 2000;32(3):203–206. doi:10.1159/000008764
   PubMed Web of Science ®Google Scholar
• Van der Graaff D, Kwanten WJ, Couturier FJ, et al. Severe steatosis induces portal hypertension by systemic arterial hyporeactivity and hepatic vasoconstrictor hyperreactivity in rats. Lab Invest. 2018;98(10):1263–1275. doi:10.1038/s41374-017-0018-z
   PubMed Web of Science ®Google Scholar
• Alessandria C, Ozdogan O, Guevara M, et al. MELD score and clinical type predict prognosis in hepatorenal syndrome: relevance to liver transplantation. Hepatology. 2005;41(6):1282–1289. doi:10.1002/hep.20687
   PubMed Web of Science ®Google Scholar
• Gilbertson EL, Krishnasamy R, Foote C, Kennard AL, Jardine MJ, Gray NA. Burden of care and quality of life among caregivers for adults receiving maintenance dialysis: a systematic review. Am J Kidney Dis. 2019;73(3):332–343. doi:10.1053/j.ajkd.2018.09.006
   PubMed Web of Science ®Google Scholar
• Terlivaz. US FDA prescribing information (terlipressin); 2022. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/022231s000lbl.pdf. Accessed October 17, 2022.
   Google Scholar
• Wong F, Pappas SC, Curry MP, et al. Terlipressin plus albumin for the treatment of type 1 hepatorenal syndrome. N Engl J Med. 2021;384(9):818–828. doi:10.1056/NEJMoa2008290
   PubMed Web of Science ®Google Scholar
• Liu Y, Meyer C, Xu C, et al. Animal models of chronic liver diseases. Am J Physiol Gastrointest Liver Physiol. 2013;304(5):G449–G468. doi:10.1152/ajpgi.00199.2012
   PubMed Web of Science ®Google Scholar